{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Verapamil", "query": { "intervention": "Verapamil" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 58, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Verapamil&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T05:18:02.745Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03070470", "title": "CiPA Phase 1 ECG Biomarker Validation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-induced QT Prolongation", "Pharmacokinetics", "Pharmacodynamics" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dofetilide and Diltiazem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Food and Drug Administration (FDA)", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": "2017-03-14", "completion_date": "2017-06-26", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03070470" }, { "nct_id": "NCT00648050", "title": "Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg", "type": "DRUG" }, { "name": "Verelan® PM Extended-Release Capsules, 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2006-03", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00648050" }, { "nct_id": "NCT03511118", "title": "Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lactating Women on Select DOI", "Breastfed Infants of Mothers on Select DOI" ], "interventions": [ { "name": "Tranexamic acid (TXA)", "type": "DRUG" }, { "name": "labetalol", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" }, { "name": "nifedipine", "type": "DRUG" }, { "name": "clindamycin", "type": "DRUG" }, { "name": "oxycodone", "type": "DRUG" }, { "name": "azithromycin", "type": "DRUG" }, { "name": "escitalopram", "type": "DRUG" }, { "name": "sertraline", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "Ciprofloxacin", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Levofloxacin", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Sumatriptan", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Cyclobenzaprine", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" }, { "name": "Gabapentin", "type": "DRUG" }, { "name": "Hydrochlorothiazide", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Topiramate", "type": "DRUG" }, { "name": "Trazodone", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Amoxicillin", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Hydrocodone", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1600, "start_date": "2018-10-04", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 20, "location_summary": "La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511118" }, { "nct_id": "NCT00578617", "title": "Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Atrial Fibrillation", "Arrhythmia" ], "interventions": [ { "name": "Rate Control", "type": "DRUG" }, { "name": "Ablation Therapy", "type": "DEVICE" }, { "name": "Rhythm control", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 60, "start_date": "2006-09", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2013-01-04", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 10, "location_summary": "Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more", "locations": [ { "city": "Birminham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00578617" }, { "nct_id": "NCT00647673", "title": "Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Verapamil HCL Extended-Release Capsules 300 mg", "type": "DRUG" }, { "name": "Verelan® PM Extended-Release Capsules 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2006-01", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2024-04-23", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00647673" }, { "nct_id": "NCT00649805", "title": "Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg", "type": "DRUG" }, { "name": "Verelan® PM Extended-Release Capsules, 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2006-01", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00649805" }, { "nct_id": "NCT01505179", "title": "The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-02", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01505179" }, { "nct_id": "NCT00518947", "title": "Pharmacotherapy of Treatment-Resistant Mania", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mania" ], "interventions": [ { "name": "Lithium", "type": "DRUG" }, { "name": "verapamil", "type": "DRUG" }, { "name": "verapamil plus lithium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "1994-11", "completion_date": "1999-06", "has_results": false, "last_update_posted_date": "2011-02-25", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00518947" }, { "nct_id": "NCT01996436", "title": "The Intra-arterial Vasospasm Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cerebral Vasospasm" ], "interventions": [ { "name": "Nicardipine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Nicardipine + Verapamil + Nitroglycerin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Peng Roc Chen, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 92, "start_date": "2016-08-29", "completion_date": "2024-08-12", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Manhasset, New York • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Manhasset", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Danville", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01996436" }, { "nct_id": "NCT03347786", "title": "Verapamil for Neuroprotection in Stroke", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ischemic Stroke" ], "interventions": [ { "name": "10 mg Intra-arterial Verapamil", "type": "DRUG" }, { "name": "20 mg Intra-arterial Verapamil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Global Neurosciences Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 60, "start_date": "2017-04-20", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-09-02T05:18:02.745Z", "location_count": 3, "location_summary": "Atlantic City, New Jersey • Langhorne, Pennsylvania • Upland, Pennsylvania", "locations": [ { "city": "Atlantic City", "state": "New Jersey" }, { "city": "Langhorne", "state": "Pennsylvania" }, { "city": "Upland", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03347786" } ] }